Want to see HK:6669 full AI Analyst Report?
6669 Stock Chart & Stats
HK$14.16
-HK$0.14(-2.42%)
At close: 4:00 PM EST
HK$14.16
-HK$0.14(-2.42%)
Day’s Range― - ―
52-Week RangeHK$5.50 - HK$15.32
Previous CloseN/A
Volume343.13K
Average Volume (3M)478.20K
Market Cap
HK$1.93B
Enterprise ValueHK$1.71K
Total Cash (Recent Filing)HK$806.80M
Total Debt (Recent Filing)HK$193.70M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding313,389,160
10 Day Avg. Volume466,437
30 Day Avg. Volume478,204
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.48
Price to Sales (P/S)5.68
P/FCF Ratio25.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.56
Revenue Forecast (FY)HK$739.92M
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe sharp improvement in net margin alongside higher revenue indicates stronger profitability and potential operating leverage. If maintained, this creates more internal funding for product development, market expansion, and clinical adoption while improving resilience across the next several quarters.
Strong Cash GenerationHigh conversion of earnings into free cash flow strengthens the company’s ability to fund operations and growth without relying heavily on external capital. This supports financial durability, although the broader record still requires continued confirmation across future reporting periods.
Conservative LeverageModest leverage and a larger equity base provide financial flexibility for a medical-device business investing in development, commercialization, and hospital coverage. Lower debt dependence can also reduce balance-sheet pressure and preserve strategic options if industry conditions become less favorable.
Bears Say
Historical Earnings VolatilityPast losses and uneven earnings indicate that the recent recovery has not yet been demonstrated through a full business cycle. Such volatility can make profitability less dependable and raises the risk that future results may fluctuate as procedure volumes, procurement, or commercialization conditions change.
Uneven Cash-flow Track RecordAlthough 2025 cash generation was healthy, the decline from the prior year and earlier periods of negative cash flow show that conversion is not consistently stable. Persistent variability could constrain self-funded expansion and make reported earnings less representative of recurring cash resources.
Gross-margin NormalizationStrong gross margin remains a benefit, but its decline from earlier unusually high levels suggests that peak profitability may not be fully sustainable. Moderate return on equity also indicates that the improved earnings base has not yet translated into especially strong capital productivity.
Acotec Scientific Holdings Limited News
6669 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
Acotec Scientific Holdings Limited lowest stock price was HK$5.50 and its highest was HK$15.32 in the past 12 months.
What is Acotec Scientific Holdings Limited’s market cap?
Acotec Scientific Holdings Limited’s market cap is HK$1.93B.
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
Acotec Scientific Holdings Limited’s upcoming earnings report date is Mar 29, 2027 which is in 184 days.
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Acotec Scientific Holdings Limited released its earnings results on Aug 31, 2026. The company reported -HK$0.315 earnings per share for the quarter.
Is Acotec Scientific Holdings Limited overvalued?
According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Overvalued.
Does Acotec Scientific Holdings Limited pay dividends?
Acotec Scientific Holdings Limited does not currently pay dividends.
What is Acotec Scientific Holdings Limited’s EPS estimate?
Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acotec Scientific Holdings Limited have?
Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Acotec Scientific Holdings Limited reported an EPS of -HK$0.315 in its last earnings report. Following the earnings report the stock price went up 0.682%.
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
Currently, no hedge funds are holding shares in HK:6669
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―